A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma

一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂

基本信息

  • 批准号:
    10397791
  • 负责人:
  • 金额:
    $ 56.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Glioblastoma is a lethal primary brain tumor with limited treatment options. The current standard therapy with combined chemoradiation therapy (chemoRT) with temozolomide (TMZ), an alkylating agent offers a median survival of only 16-18 months. There is an urgent need for novel therapies especially those that can overcome resistance to chemoRT. Cancer cells develop complex resistance mechanisms that enable them to survive the effects of conventional therapies. One such evolutionally conserved mechanism is the heat shock response (HSR) which can deploy several diverse defense processes in the setting of adverse environmental conditions. The HSR is mediated by heat shock proteins (HSP), a class of molecular chaperones that shuttle and configure client oncoproteins into proper functional states. In preliminary studies, we show that onalespib, a novel long acting inhibitor of heat shock protein 90 (Hsp90), a critical mediator of the HSR in cancer cells, blocked tumor growth, invasion and angiogenesis in gliomas suggesting the potential for a strong independent antitumor effect. Relevant to this proposal, onalespib sensitizes glioma cells to TMZ and RT in patient-derived (PDX) cell lines and in a zebrafish and mouse intracranial glioma animal models. Based on these data, in this grant submission, we propose a phase I clinical trial through the NCI-funded Adult Brain Tumor Consortium to identify the maximum tolerated dose of the combination of onalespib with chemoRT in adults with newly diagnosed GBM. We also propose to conduct key correlative tissue and plasma studies through the following specific aims: Aim 1 will identify the MTD of onalespib in combination of chemoRT and adjuvant temozolomide and will determine whether onalespib can cross the blood brain barrier and achieve sufficient concentrations in enhancing and non-enhancing glioma tissue compared with plasma levels. Aim 2 will determine the pharmacodynamic effects of onalespib by assessing whether onalespib can inhibit Hsp90, its target, in human GBM tissue obtained in this trial and whether this inhibition can affect its chaperone oncoprotein clients particularly those relevant to DNA repair and cell survival against the effects of RT and TMZ. In Aim 3, we will conduct co-clinical trials using PDX intracranial glioma models and organotypic human glioma slices to determine the mechanisms of sensitivity and resistance to onalespib effects to provide insights that can help modify the subsequent phase II trial. This is the first human trial of an Hsp90 inhibitor in brain tumors and the first to combine an Hsp90 inhibitor with chemo- and radiation therapy against GBM. Successful completion of this trial will enable us to proceed to a Phase II efficacy trial (approved by NRG oncology) and will provide comprehensive PK and PD data that can help the development of onalespib and Hsp90 inhibitors in other malignancies.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VINAY K PUDUVALLI其他文献

VINAY K PUDUVALLI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VINAY K PUDUVALLI', 18)}}的其他基金

A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
  • 批准号:
    10480888
  • 财政年份:
    2019
  • 资助金额:
    $ 56.07万
  • 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
  • 批准号:
    10687871
  • 财政年份:
    2019
  • 资助金额:
    $ 56.07万
  • 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
  • 批准号:
    8731813
  • 财政年份:
    2012
  • 资助金额:
    $ 56.07万
  • 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
  • 批准号:
    8846550
  • 财政年份:
    2012
  • 资助金额:
    $ 56.07万
  • 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
  • 批准号:
    8459885
  • 财政年份:
    2012
  • 资助金额:
    $ 56.07万
  • 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
  • 批准号:
    8300649
  • 财政年份:
    2012
  • 资助金额:
    $ 56.07万
  • 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
  • 批准号:
    7167160
  • 财政年份:
    2006
  • 资助金额:
    $ 56.07万
  • 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
  • 批准号:
    7340756
  • 财政年份:
    2006
  • 资助金额:
    $ 56.07万
  • 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
  • 批准号:
    7749939
  • 财政年份:
    2006
  • 资助金额:
    $ 56.07万
  • 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
  • 批准号:
    7033212
  • 财政年份:
    2006
  • 资助金额:
    $ 56.07万
  • 项目类别:

相似国自然基金

分子伴侣Hsp90/FKBP51复合物通过稳定PPARγ减轻糖尿病心缺血再灌注损伤的机制研究
  • 批准号:
    JCZRYB202500986
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
西花蓟马热休克蛋白Hsp90与番茄斑萎病毒NSs蛋白互作调控介体传毒机制研究
  • 批准号:
    2025JJ60138
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
HSP90介导的新型GPX4降解剂的设计、合成及铁死亡响应的抗肿瘤耐药研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
转录相关蛋白Tap1介导热休克蛋白Hsp90乙酰化在白念珠菌致病性中的作用机制研究
  • 批准号:
    QN25H110013
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
响应性纳米材料靶向抑制Hsp90的内耳保护效应及机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
激光热疗经肿瘤细胞分泌富含HSP90的外泌体激活NLRP3介导巨噬细胞M1极化的机制研究
  • 批准号:
    2025JJ70425
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
HSP90抑制剂改善 KRAS/STK11 共突变肺腺癌抗 PD-L1 免疫治疗原发耐药的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
热休克蛋白HSP90α乳酸化修饰通过 ACT1/STAT3/HMGB1通路对糖尿病创面愈 合的调控及机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目

相似海外基金

Novel small molecule HSP90 inhibitor for the management of atopic dermatitis
用于治疗特应性皮炎的新型小分子 HSP90 抑制剂
  • 批准号:
    10016726
  • 财政年份:
    2020
  • 资助金额:
    $ 56.07万
  • 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
  • 批准号:
    10480888
  • 财政年份:
    2019
  • 资助金额:
    $ 56.07万
  • 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
  • 批准号:
    10687871
  • 财政年份:
    2019
  • 资助金额:
    $ 56.07万
  • 项目类别:
A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis
一种治疗轻至中度斑块状银屑病的新型外用 HSP90 抑制剂 (CTXT-102)
  • 批准号:
    9572916
  • 财政年份:
    2017
  • 资助金额:
    $ 56.07万
  • 项目类别:
Development of novel molecular targeted therapy for rejection after organ transplantation using HSP90 inhibitor
使用HSP90抑制剂开发针对器官移植后排斥反应的新型分子靶向疗法
  • 批准号:
    15K20099
  • 财政年份:
    2015
  • 资助金额:
    $ 56.07万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of novel molecular targeted therapies for the treatment of KRas mutated non small lung cancer using a HSP90 inhibitor
使用 HSP90 抑制剂开发治疗 KRas 突变非小细胞肺癌的新型分子靶向疗法
  • 批准号:
    23592078
  • 财政年份:
    2011
  • 资助金额:
    $ 56.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting HSP90 in prostate cancer bone microenvironment by using a novel inhibitor: SNX-5422
使用新型抑制剂:SNX-5422 靶向前列腺癌骨微环境中的 HSP90
  • 批准号:
    203479
  • 财政年份:
    2010
  • 资助金额:
    $ 56.07万
  • 项目类别:
    Fellowship Programs
Specific inhibition of heat-shock-protein 90 (Hsp90) by a novel peptidomimetic inhibitor shepherdin in malignant glioma cells
新型拟肽抑制剂 Shepherdin 对恶性胶质瘤细胞中热休克蛋白 90 (Hsp90) 的特异性抑制
  • 批准号:
    125479995
  • 财政年份:
    2009
  • 资助金额:
    $ 56.07万
  • 项目类别:
    Research Fellowships
Investigation of novel therapeutic alternative to gastrointestinal cancer using a HSP90 inhibitor
使用 HSP90 抑制剂研究胃肠癌的新型治疗替代方案
  • 批准号:
    21591700
  • 财政年份:
    2009
  • 资助金额:
    $ 56.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Preclinical Evaluation of a Novel Hsp90 inhibitor in Mutant Tau Mice
新型 Hsp90 抑制剂在 Tau 突变小鼠中的临床前评估
  • 批准号:
    7464465
  • 财政年份:
    2008
  • 资助金额:
    $ 56.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了